Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582384 | 1.00 | CHRNA7 (0.49) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL27598256 | 1.00 | CHRNA7 (0.49) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL1900169 | 0.81 | PTPN1 (0.39) | SCN1ASCN2ASCN3APTPN2PTPN1 | |
| SCHEMBL28339381 | 0.78 | CHRNA7 (0.56) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL15193256 | 0.78 | CHRNA7 (0.56) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL12689962 | 0.77 | HTT (0.37) | HTR3AMAPTLMNA | |
| SCHEMBL6561804 | 0.75 | HTT (0.47) | CHRNA7MEN1KMT2ATSHRMAPT | |
| SCHEMBL6560271 | 0.75 | HTT (0.47) | CHRNA7MEN1KMT2ATSHRMAPT | |
| SCHEMBL4453290 | 0.75 | MEN1 (0.69) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL1786140 | 0.75 | MEN1 (0.69) | CHRNA7MEN1KMT2AGAAHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090104669-A1 | Method for Preparing (S)-3-Hydroxy-Gamma-Butyrolactone Using Hydrolase | LG CHEM, LTD. (KR) | 2009-04-23 | — | — | US | claimed |
| WO-2007100227-A1 | METHOD FOR PREPARING (S)-3-HYDROXY-GAMMA-BUTYROLACTONE USING HYDROLASE | LG CHEM, LTD. (KR) | 2007-09-07 | — | — | WO | claimed |
| CN-1483730-A | 'Beta'-substituted-'gamma'-butyrolactone | 鱼洪善 | 2004-03-24 | — | — | CN | claimed |
| EP-1398312-A1 | Beta-substituted-gamma-butyrolactones and a process for preparation thereof | Uh, Hong-Sun (KR) | 2004-03-17 | — | — | EP | claimed |
| US-9522932-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-12-20 | — | — | US | disclosed |
| US-9522932-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-12-20 | — | — | US | disclosed |
| EP-2980095-A1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U.Leuven Research & Development (BE) | 2016-02-03 | — | — | EP | disclosed |
| US-9249177-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-02-02 | — | — | US | disclosed |
| US-9249177-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-01-14 | — | — | US | disclosed |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-01-14 | — | — | US | disclosed |
| EP-1720890-B1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | LEUVEN K U RES & DEV (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-8076310-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-12-13 | — | — | US | disclosed |
| US-20090104669-A1 | Method for Preparing (S)-3-Hydroxy-Gamma-Butyrolactone Using Hydrolase | LG CHEM, LTD. (KR) | 2009-04-23 | — | — | US | disclosed |
| US-20090104669-A1 | Method for Preparing (S)-3-Hydroxy-Gamma-Butyrolactone Using Hydrolase | LG CHEM, LTD. (KR) | 2009-04-23 | — | — | US | disclosed |
| WO-2007100227-A1 | METHOD FOR PREPARING (S)-3-HYDROXY-GAMMA-BUTYROLACTONE USING HYDROLASE | LG CHEM, LTD. (KR) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100227-A1 | METHOD FOR PREPARING (S)-3-HYDROXY-GAMMA-BUTYROLACTONE USING HYDROLASE | LG CHEM, LTD. (KR) | 2007-09-07 | — | — | WO | disclosed |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-09 | — | — | US | disclosed |
| CN-1483730-A | 'Beta'-substituted-'gamma'-butyrolactone | 鱼洪善 | 2004-03-24 | — | — | CN | disclosed |
| EP-1398312-A1 | Beta-substituted-gamma-butyrolactones and a process for preparation thereof | Uh, Hong-Sun (KR) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | ENTPD5, PPA1, TYMP | CHRNA7 4371/4885MEN1 4118/4885KMT2A 3980/4885 |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | CHRNA7 3890/4885MEN1 3861/4885KMT2A 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.